Dossier assessment

Baricitinib (atopic dermatitis, 2 to 17 years) – Benefit assessment according to §35a Social Code Book V

Report documents

Indication:

Paediatric patients 2 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy

Result of dossier assessment:

Children 2 to 5 years of age with moderate to severe atopic dermatitis: added benefit not proven
Children 6 to 11 years of age with moderate atopic dermatitis: added benefit not proven
Children 6 to 11 years of age with severe atopic dermatitis: added benefit not proven
Adolescents 12 to 17 years of age with moderate to severe atopic dermatitis: added benefit not proven

Project no.: A23-109
Commission: Commission awarded on 14.11.2023 by the Federal Joint Committee (GBA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Skin and hair
Note: After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
DOI: https://doi.org/10.60584/A23-109

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.